<DOC>
	<DOCNO>NCT02006030</DOCNO>
	<brief_summary>Certain cancer require amino acid arginine . Arginine deiminase ( ADI ) enzyme microbe degrade arginine . ADI formulate polyethylene glycol use treat patient cancer require arginine . In study , investigator evaluate response rate , determine revise International Working Group recommendation .</brief_summary>
	<brief_title>Ph 2 Trial ADI PEG 20 Plus Concurrent Transarterial Chemoembolization ( TACE ) Vs TACE Alone Patients With Unresectable Hepatocellular Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<criteria>1 . Diagnosis HCC confirm clinically histologically cytologically . A clinical diagnosis HCC , use 2010 Guideline American Association Study Liver Diseases require presence hepatic tumor ( ) image finding ( e.g . sonography , CT MRI ) compatible HCC , evidence gastrointestinal tumor ( Bruix [ 2011 ] Guideline , 2010 ) . 2 . Solitary hepatic tumor &lt; 8 cm diameter multifocal disease evidence CT MRI scan . Tumor volume ≥50 % liver organ infiltrate HCC exclude . 3 . Not candidate surgical resection ablation tumor . 4 . The target lesion must treat previously local therapy , include TACE . Prior local therapy ( radiofrequency ablation , percutaneous ethanol injection , cryoablation , surgery ) nontarget lesion acceptable . 5 . The subject must receive 2 TACE ( n≤ 2 ) previous TACE perform longer 2 month enrollment . 6 . Local therapy must complete least 4 week baseline scan . 7 . Measurable disease use mRECIST criterion ( Appendix A ) RECIST1.1 ( Appendix B ) criterion . At least 1 measurable lesion must present . 8 . Barcelona Clinic Liver Cancer ( BCLC ) stag classification B ( intermediate stage ) ( Appendix C ) . 1 . 1 . Candidate potential curative therapy ( i.e. , resection transplantation ) . 2 . Prior allograft transplantation include liver transplantation . 3 . Significant cardiac disease ( New York Heart Association Class III IV ; Appendix F ) . 4 . Serious infection require treatment systemically administer antibiotic . 5 . Pregnancy lactation . 6 . Expected noncompliance . 7 . Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure ( New York Heart Association Class III IV ) , unstable angina pectoris , cardiac arrhythmia , psychiatric illness social situation would limit compliance study requirement . 8 . Subjects anticancer treatment within 2 week prior week 1 visit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Unresectable Hepatocellular Carcinoma</keyword>
	<keyword>Liver Cancer</keyword>
	<keyword>ADI</keyword>
	<keyword>ADI-PEG 20</keyword>
</DOC>